De novo design of drug-binding proteins with predictable binding energy and specificity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38574125.
- Also identified by DOI 10.1126/science.adl5364 and PMC identifier 11290694.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The de novo design of small molecule-binding proteins has seen exciting recent progress; however, high-affinity binding and tunable specificity typically require laborious screening and optimization after computational design. We developed a computational procedure to design a protein that recognizes a common pharmacophore in a series of poly(ADP-ribose) polymerase-1 inhibitors. One of three designed proteins bound different inhibitors with affinities ranging from <5 nM to low micromolar. X-ray crystal structures confirmed the accuracy of the designed protein-drug interactions. Molecular dynamics simulations informed the role of water in binding. Binding free energy calculations performed directly on the designed models were in excellent agreement with the experimentally measured affinities. We conclude that de novo design of high-affinity small molecule-binding proteins with tuned interaction energies is feasible entirely from computation.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Proteins
- Protein Engineering
- Pharmacophore